Treatment of Primary Central Nervous System Posttransplant Lymphoproliferative Disorder in an Adult Kidney Transplant Recipient: A Case Report.
Exp Clin Transplant
; 17(1): 111-114, 2019 02.
Article
em En
| MEDLINE
| ID: mdl-28447926
ABSTRACT
Posttransplant lymphoproliferative disorder is a serious complication of solid-organ transplant. Extranodal involvement is common; however, isolated involvement of the central nervous system is extremely rare and represents a particularly difficult therapeutic challenge with no current consensus on optimal treatment. Here, we describe a 70-year-old woman who developed Epstein-Barr virus-related primary central nervous system lymphoma 19 months after kidney transplant. Immunosuppression was reduced, and the patient was started on high-dose methotrexate, which was complicated by acute kidney injury and discontinued. She then received a rituximab and temozolomide chemotherapeutic regimen and achieved complete clinical response. Seventeen months after diagnosis, she is alive and has not developed any other posttransplant lymphoproliferative disorder. We review the current literature and discuss treatment options for patients with primary central nervous system posttransplant lymphoproliferative disorder following kidney transplant.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Protocolos de Quimioterapia Combinada Antineoplásica
/
Transplante de Rim
/
Neoplasias do Sistema Nervoso Central
/
Infecções por Vírus Epstein-Barr
/
Rituximab
/
Temozolomida
/
Linfoma
Tipo de estudo:
Diagnostic_studies
Limite:
Aged
/
Female
/
Humans
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article